354 related articles for article (PubMed ID: 19126567)
1. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Moriya T
J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
[TBL] [Abstract][Full Text] [Related]
2. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
3. Papillary lesions of the breast: selected diagnostic and management issues.
Collins LC; Schnitt SJ
Histopathology; 2008 Jan; 52(1):20-9. PubMed ID: 18171414
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture].
MacGrogan G
Ann Pathol; 2009 Jun; 29(3):188-93. PubMed ID: 19619824
[No Abstract] [Full Text] [Related]
5. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
[TBL] [Abstract][Full Text] [Related]
6. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
[TBL] [Abstract][Full Text] [Related]
7. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
Raju UB; Lee MW; Zarbo RJ; Crissman JD
Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
Tan PH; Lui GG; Chiang G; Yap WM; Poh WT; Bay BH
Histopathology; 2004 Oct; 45(4):343-51. PubMed ID: 15469472
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
Grin A; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
[TBL] [Abstract][Full Text] [Related]
10. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
11. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions.
Moriya T; Kanomata N; Kozuka Y; Fukumoto M; Iwachido N; Hata S; Takahashi Y; Miura H; Ishida K; Watanabe M
Breast Cancer; 2009; 16(3):173-8. PubMed ID: 19475479
[TBL] [Abstract][Full Text] [Related]
13. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S;
Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281
[TBL] [Abstract][Full Text] [Related]
14. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63.
Douglas-Jones A; Shah V; Morgan J; Dallimore N; Rashid M
Histopathology; 2005 Aug; 47(2):202-8. PubMed ID: 16045782
[TBL] [Abstract][Full Text] [Related]
15. Papillary lesions of the breast: a molecular progression?
Di Cristofano C; Mrad K; Zavaglia K; Bertacca G; Aretini P; Cipollini G; Bevilacqua G; Ben Romdhane K; Cavazzana A
Breast Cancer Res Treat; 2005 Mar; 90(1):71-6. PubMed ID: 15770529
[TBL] [Abstract][Full Text] [Related]
16. Breast pathology practice: most common problems in a consultation service.
Putti TC; Pinder SE; Elston CW; Lee AH; Ellis IO
Histopathology; 2005 Nov; 47(5):445-57. PubMed ID: 16241992
[TBL] [Abstract][Full Text] [Related]
17. The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best.
Reisenbichler ES; Adams AL; Hameed O
Am J Clin Pathol; 2013 Dec; 140(6):767-79. PubMed ID: 24225742
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry in the diagnosis of papillary lesions of the breast.
Tse GM; Ni YB; Tsang JY; Shao MM; Huang YH; Luo MH; Lacambra MD; Yamaguchi R; Tan PH
Histopathology; 2014 Dec; 65(6):839-53. PubMed ID: 24804569
[TBL] [Abstract][Full Text] [Related]
19. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
